How do you approach the treatment of de novo, brain only metastatic HER2 positive breast cancer?

Answer from: Medical Oncologist at Academic Institution

Patients who present with de novo, brain-only metastases of HER2+ breast cancer are rare, and hence, there is no good clinical experience or clinical trial basis upon which to base clinical practice recommendations. The current ASCO guidelines for the management of HER2+ brain metastases call for ap...

Comments

Medical Oncologist at Hoag Health System
Would anyone use tucatinib+tras+/-xeloda based on ...

Medical Oncologist at University of Texas MD Anderson Cancer Center
It is appealing to add cytotoxic therapy in a situ...

Medical Oncologist at Baylor-Charles A Sammons Cancer Center
Would this maintenance period of HP be long term v...

Medical Oncologist at University of Texas MD Anderson Cancer Center
For patients with metastatic disease, the conventi...

Answer from: Medical Oncologist at Academic Institution

I think these patients should be evaluated for localized CNS therapy, especially if they are symptomatic. After completion of CNS-directed therapy, I would either proceed with standard-of-care first-line systemic therapy THP or consider the use of T-DXd if able to obtain insurance approval.

Please select the option that best describes you:

How do you approach the treatment of de novo, brain only metastatic HER2 positive breast cancer?

Related Questions